Skip to main content
. 2019 Nov 5;2019:8483650. doi: 10.1155/2019/8483650

Figure 2.

Figure 2

BAFF/BLyS and APRIL baseline serum levels in PMN patients and in controls. (a) BAFF/BLyS baseline serum levels in PMN patients with anti-PLA2R antibodies are significantly higher than those in patients without anti-PLA2R antibodies (5.64 ± 0.97 vs. 1.08 ± 0.33 ng/mL, p < 0.001; white and gray histogram, respectively), while no significant difference was observed with those from patients with lupus nephritis (6.01 ± 2.68 ng/mL, p = 0.09; dark gray histogram). Finally, in healthy volunteers, BAFF/BLyS was detected at very low concentration (0.31 ± 0.21 ng/mL, p = 0.12 vs. PLA2R-negative patients; black histogram). (b) APRIL baseline serum levels in PMN patients with anti-PLA2R antibodies are significantly higher than those in patients without anti-PLA2R antibodies (3.62 ± 0.84 vs. 1.08 ± 0.33 ng/mL, p < 0.001; white and gray histogram, respectively), while no significant difference was observed with those from patients with lupus nephritis (4.09 ± 2.24 ng/mL, p = 0.18; dark gray histogram). Finally, in healthy volunteers, APRIL was detected at very low concentration (0.52 ± 0.32 ng/mL, p = 0.27 vs. PLA2R-negative patients; black histogram). Mann-Whitney U test for nonparametric data. Data in the graphs are expressed as mean ± standard deviation.